Scientific Publications

Poly (ADP-ribose) Drives Pathologic α-Synuclein Neurodegeneration in Parkinson’s Disease.

T. I. Kam, X. Mao, H. Park, S-C Chou, S. S. Karuppagounder, G. E. Umanah, S. P. Yun, S. Brahmachari, N. Panicker, R. Chen, S. A. Andrabi, C. Qi, G. G. Poirier, O. Pletnikova, J. C. Troncoso, L. M. Bekris, J. B. Leverenz, A. Pantelyat, H. S. Ko, L. S. Rosenthal, T. M. Dawson and V. L. Dawson. Poly (ADP-ribose) Drives Pathologic alpha-Synuclein Neurodegeneration in Parkinson’s Disease, Science 362, pii: eaat8407. doi: 10.1126/science.aat8407, (2018).

View Publication

Natalizumab-treated Patients at High Risk for PML Persistently Excrete JC Polyomavirus

Werner GA and Huang D (2016) Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus. J Neurovirol. 2016 Dec;22(6):871-875.

View Publication

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM. (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. Sep 30;353(6307). pii: aah3374.

View Publication

Pathological α-synuclein Transmission Initiated by Binding Lymphocyte-activation Gene 3

Mao, M. T. Ou, S. S. Karuppagounder, T. I. Kam, X. Yin, Y. Xiong, P. Ge, G. E. Umanah, S. Brahmachari, J. H. Shin, H. C. Kang, J. Zhang, J. Xu, R. Chen, H. Park, S. A. Andrabi, S. U. Kang, R. A. Gonçalves, Y. Liang, S. Zhang, C. Qi, S. Lam, J. A. Keiler, J. Tyson, D. Kim, N. Panicker, S. P. Yun, C. J. Workman, D. A. Vignali, V. L. Dawson, H. S. Ko, T. M. Dawson. (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science353:aah374.

View Publication

Reassessing the Risk of Natalizumab-associated PML

Berger JR, Fox RJ.  (2016) Reassessing the risk of natalizumab-associated PML.  J Neurovirol. 2016 Aug;22(4):533-5.

View Publication

Nilotinib – Differentiating the Hope from the Hype

Wyse RK, Brundin P, Sherer TB.  (2016) Nilotinib – Differentiating the Hope from the Hype. J Parkinsons Dis. 2016 Jul 12.

View Publication

Nilotinib Effects in Parkinson’s Disease and Dementia with Lewy Bodies

Pagan F, Hebron M, Valadez EH, Tores-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Drew Falconer R, Ahn J, Li Z, Moussa C.  (2016) Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies.  J Parkinsons Dis. 2016 Jul 11.

View Publication

Activation of Tyrosine Kinase c-Abl Contributes to α-synuclein-Induced Neurodegeneration

Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS.  (2016) Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.  J Clin Invest. 126:2970-88.

View Publication

Targeting α-synuclein for Treatment of Parkinson’s Disease: Mechanistic and Therapeutic Considerations

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. (2015) Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14:855-66.

View Publication

New Tricks for Old Dogs: Countering Antibiotic Resistance in Tuberculosis with Host-directed Therapeutics

Hawn TR, Shah JA, Kalman D. (2015) New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev. Mar;264(1):344-62.

View Publication